Literature DB >> 8203715

Proguanil plus sulfamethoxazole is not causally prophylactic in the Macaca mulatta--Plasmodium cynomolgi model.

G D Shanks1, M D Edstein, A L Chedester, C D Smith, K D Corcoran, M Ngampochjana, P Hansukjariya, J Sattabongkot, H K Webster.   

Abstract

New drugs for causal prophylaxis of malaria are needed. A proguanil/sulfamethoxazole combination was investigated using a rhesus monkey model (Macaca mulatta infected with Plasmodium cynomolgi) to determine whether causal prophylaxis could be achieved. When a five-day regimen of proguanil (40 mg/kg/day) combined with sulfamethoxazole (100 mg/kg/day) was used, infection of all animals (6 of 6) was observed, with an extended prepatent period (median 40 days). Two control animals became infected on days 9 and 23 following sporozoite inoculation. Plasma concentrations indicated that proguanil and sulfamethoxazole were adequately absorbed and metabolized to cycloguanil and N4-acetylsulfamethoxazole, respectively. Analysis of liver biopsy specimens demonstrated that the drugs were present two days following sporozoite inoculation but were not detectable one week later. Proguanil plus sulfamethoxazole does not eliminate exoerythrocytic-stage parasites in the rhesus monkey--P. cynomolgi model.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8203715     DOI: 10.4269/ajtmh.1994.50.641

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  3 in total

1.  The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria.

Authors:  R McGready; K Stepniewska; M D Edstein; T Cho; G Gilveray; S Looareesuwan; N J White; F Nosten
Journal:  Eur J Clin Pharmacol       Date:  2003-08-30       Impact factor: 2.953

2.  HIV treatments reduce malaria liver stage burden in a non-human primate model of malaria infection at clinically relevant concentrations in vivo.

Authors:  Charlotte V Hobbs; Jillian Neal; Solomon Conteh; Liam Donnelly; Jingyang Chen; Kennan Marsh; Lynn Lambert; Sachy Orr-Gonzalez; Jessica Hinderer; Sara Healy; William Borkowsky; Scott R Penzak; Sumana Chakravarty; Stephen L Hoffman; Patrick E Duffy
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

3.  Neither the HIV protease inhibitor lopinavir-ritonavir nor the antimicrobial trimethoprim-sulfamethoxazole prevent malaria relapse in plasmodium cynomolgi-infected non-human primates.

Authors:  Charlotte V Hobbs; Saurabh Dixit; Scott R Penzak; Tejram Sahu; Sachy Orr-Gonzalez; Lynn Lambert; Katie Zeleski; Jingyang Chen; Jillian Neal; William Borkowsky; Yimin Wu; Patrick E Duffy
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.